Merck and Moderna to file personalized mRNA cancer vaccine after Phase 3 success
Start here
Merck and Moderna are preparing to seek approval for intismeran autogene, their personalized mRNA cancer vaccine, after a large Phase 3 trial showed it significantly delayed cancer recurrence and metastatic disease in melanoma patients when combined with Keytruda. Moderna President Stephen Hoge and Merck R&D chief Dean Li, speaking at the STAT Summit, said the companies will prioritize expanding into settings where Keytruda works best. Adjuvant trials in lung, kidney, bladder, pancreatic and gastric cancer are already underway or beginning. Open questions include how far the vaccine-Keytruda combination can extend across the companies' trial pipeline and what regulators will require for approval.
Written by a model from the reports · updated 2 min ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickDetailed Phase 3 Data for intismeran autogene Plus Keytruda in Melanoma Show 42% Lower Recurrence or Death Risk
Merck and Moderna have announced detailed Phase 3 results for the personalized mRNA cancer therapy intismeran autogene combined with Keytruda (pembrolizumab) in melanoma. Compared with Keytruda alone, the combination reduced the risk of disease recurrence or death by 42%.
- biospace.comESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak
Phase 3 INTerpath-001 melanoma data leaked ahead of ESMO 2026. Intismeran autogene plus Keytruda met the primary endpoint, with an RFS hazard ratio of 0.58, corresponding to a 42% reduction in the risk of recurrence or death.
- biopharmadive.comPickModerna, Merck shares fall on eagerly anticipated cancer vaccine results
Moderna and Merck's intismeran autogene combined with Keytruda reduced the relative risk of disease recurrence or death by 42% versus Keytruda alone in a late-stage trial in post-surgery melanoma, with a median follow-up of 24.6 months.
- statnews.comSTAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial
Moderna and Merck's personalized mRNA cancer vaccine intismeran autogene met key endpoints in a melanoma clinical trial, reducing the risk of disease recurrence by 42% compared to standard treatment. The results showed patients lived significantly longer without their cancer returning. The therapy targets unique mutations in patients' tumors called neoantigens.
- mp.weixin.qq.comPickINTerpath-001 Data Reportedly Leaked Ahead of ESMO 2026, Moderna Shares Plunge
Detailed INTerpath-001 data appear to have leaked ahead of ESMO 2026, raising efficacy questions and sending Moderna shares sharply lower. According to the original report, after a median follow-up of 24.6 months, adding intismeran to pembrolizumab reduced the risk of recurrence or death, HR = 0.58. At 2 years, 82.2% of patients on the combination were alive and recurrence-free versus 70.0% on pembrolizumab alone.
- biocentury.comPickModerna’s melanoma vaccine data bring adoption test into focus
Moderna's personalized cancer vaccine intismeran autogene combined with Keytruda reduced the risk of recurrence or death by 42% in a Phase III melanoma trial (HR=0.58, p<0.001), validating the benefit of personalized vaccines in adjuvant therapy. But the therapy faces challenges from personalized manufacturing complexity, high costs, and competition from neoadjuvant immunotherapy strategies, and the trial did not directly compare against neoadjuvant regimens, so commercial adoption remains to be weighed.
- statnews.comMerck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine success
Merck and Moderna are preparing to file their personalized mRNA cancer vaccine, intismeran autogene, for approval after a large Phase 3 trial showed it significantly delayed cancer recurrence and metastatic disease in melanoma patients when combined with Keytruda. Speaking at the STAT Summit, Moderna President Stephen Hoge and Merck R&D chief Dean Li said they will prioritize expansion into settings where Keytruda works best, with adjuvant lung, kidney, bladder, pancreatic and gastric cancer trials already underway or beginning.
- statnews.comAfter a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward
Gary Keblish, a schoolteacher treated in a late-stage trial of intismeran autogene, the mRNA cancer vaccine from Merck and Moderna, shared his story at the STAT Summit in Boston. Diagnosed with high-risk melanoma in 2019, he received the vaccine alongside Keytruda and described neuropathy during treatment. His tumor was removed six years ago and he continues teaching; the companies reported promising trial results in August.
- mp.weixin.qq.comPickFirst Phase III Success for Individualized Neoantigen mRNA Cancer Vaccine
An mRNA cancer therapeutic vaccine has delivered a positive Phase III readout, the first individualized neoantigen therapy and the first mRNA tumor treatment product to succeed at Phase III. The trial enrolled 1137 patients randomized 2:1. The result establishes that this development route can work, not that vaccines cure cancer.
- statnews.comCould we one day vaccinate against every cancer?
The 2026 Nobel Prize in Physiology or Medicine went to Karl Deisseroth, Peter Hegemann and Georg Nagel for discoveries concerning light-gated ion channels and optogenetics, a method using light plus genetic modifications of neurons to switch individual brain cells on or off. The work makes it possible to show how nerve cells shape memories, feelings and behavior, and is being studied as a treatment for disease.
- statnews.comSTAT+: Divergent trial results on cancer vaccines have the field grappling with hard questions
A late-stage mRNA cancer vaccine has shown it stopped the return of melanoma, boosting hopes that the approach can be turned against other cancers. Merck and Moderna reported in August that adding their vaccine, intismeran autogene, to an existing treatment slowed the return and spread of melanoma. The open questions are which cancers to target next and whether mRNA can meet the task.
Heat trend for this story
Heat now 36·Peak in the comparable set 47 (Oct 23 06:00)·Change over 24h in the comparable set +8775%·Participants now 6
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.